Sacyl Pharmaceuticals
$100,000 Awarded January 2023 |
Sacyl PharmaceuticalsNew York, NY
About
Sacyl Pharmaceuticals, Inc. is working towards innovative contraceptive solutions, leveraging the genetically and pharmacologically validated contraceptive target soluble adenylyl cyclase (sAC; ADCY10) into on-demand options for men. Our Grant
MCI’s support facilitates the development of novel sAC inhibitors as on-demand contraceptives for men by optimizing the safety and efficacy of new compounds. These steps are crucial to overcome the high bar that will be required of any new contraceptive product. |
Publications
Miller, M., Rossetti, T., Ferreira, J., Ghanem, L., Balbach, M., Kaur, N., Levin, L. R., Buck, J., Kehr, M., Coquille, S., van den Heuvel, J., Steegborn, C., Fushimi, M., Finkin-Groner, E., Myers, R. W., Kargman, S., Liverton, N. J., Huggins, D. J., & Meinke, P. T. (2022). Design, Synthesis, and Pharmacological Evaluation of Second-Generation Soluble Adenylyl Cyclase (sAC, ADCY10) Inhibitors with Slow Dissociation Rates. Journal of medicinal chemistry, 65(22), 15208–15226. https://doi.org/10.1021/acs.jmedchem.2c01133
Rossetti, T., Ferreira, J., Ghanem, L., Buck, H., Steegborn, C., Myers, R. W., Meinke, P. T., Levin, L. R., & Buck, J. (2022). Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential. Frontiers in physiology, 13, 1013845. https://doi.org/10.3389/fphys.2022.1013845
Miller, M., Rossetti, T., Ferreira, J., Ghanem, L., Balbach, M., Kaur, N., Levin, L. R., Buck, J., Kehr, M., Coquille, S., van den Heuvel, J., Steegborn, C., Fushimi, M., Finkin-Groner, E., Myers, R. W., Kargman, S., Liverton, N. J., Huggins, D. J., & Meinke, P. T. (2022). Design, Synthesis, and Pharmacological Evaluation of Second-Generation Soluble Adenylyl Cyclase (sAC, ADCY10) Inhibitors with Slow Dissociation Rates. Journal of medicinal chemistry, 65(22), 15208–15226. https://doi.org/10.1021/acs.jmedchem.2c01133
Rossetti, T., Ferreira, J., Ghanem, L., Buck, H., Steegborn, C., Myers, R. W., Meinke, P. T., Levin, L. R., & Buck, J. (2022). Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential. Frontiers in physiology, 13, 1013845. https://doi.org/10.3389/fphys.2022.1013845
Sacyl Pharmaceuticals In the News:
- "Male Birth Control Drug Sees ‘Game-Changer’ Trial In Mice—Here’s What You Need To Know" in Forbes
- "Quick-acting male birth control drug shows promise in the lab" by The Washington Post
- "Male birth control research wins audience over at STAT Madness event" from STAT
- "Male contraceptive pill created – but it has to be taken right before sex" in METRO
- "Male contraceptive disables sperm" from the National Institutes of Health
Meet MCI's Grantees & Fellows!
Our grantees and fellows represent some of the finest minds in the male contraception research community from around the world.
At Male Contraceptive Initiative, we prioritize funding research that aligns with our mission of driving male contraception closer to clinical trials. We strategically allocate our resources to support a diverse range of projects, focusing on non-hormonal and reversible methods that have the potential to meet the needs of a broader population. Our goal is to catalyze progress in this field and bring innovative male birth control options to market.
Discover the innovative research being conducted by our grantees and fellows by clicking on the buttons below:
At Male Contraceptive Initiative, we prioritize funding research that aligns with our mission of driving male contraception closer to clinical trials. We strategically allocate our resources to support a diverse range of projects, focusing on non-hormonal and reversible methods that have the potential to meet the needs of a broader population. Our goal is to catalyze progress in this field and bring innovative male birth control options to market.
Discover the innovative research being conducted by our grantees and fellows by clicking on the buttons below:
